Treatment Options for HER2+ Breast Cancer Are Now Differentiated by Genomic Assay.

Published Date: 20 May 2023

A group of Spanish oncologists changed treatment plans for 56 percent of 89 patients with HER2-positive (HER2+) early breast cancer as a result of the prognostic genomic assay's findings.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

2.

Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer

3.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

4.

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

5.

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot